Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60308
UPID:
CE104_HUMAN
Alternative names:
-
Alternative UPACC:
O60308; A0A024R4G3; Q5JSQ3; Q5SR24; Q5SR25; Q6PKF5; Q86W32; Q86X14
Background:
Centrosomal protein of 104 kDa (Cep104) is pivotal for ciliogenesis and maintaining the structural integrity at the ciliary tip. This protein plays a crucial role in the formation and function of cilia, which are essential for cell signaling and homeostasis.
Therapeutic significance:
Cep104's involvement in Joubert syndrome 25 and Intellectual developmental disorder, autosomal recessive 77, highlights its potential as a therapeutic target. Understanding the role of Centrosomal protein of 104 kDa could open doors to potential therapeutic strategies for these neurodevelopmental disorders.